FTSE 100 today: Index gains hold, Burberry recovers, GSK drags on FDA ruling

British stocks posted modest gains, with the FTSE 100 up 0.2%, amidst significant corporate developments. GSK shares fell over 6% following an FDA advisory panel's negative vote on its cancer treatment Blenrep, citing risks outweighing benefits. In contrast, Burberry exceeded sales expectations with a smaller-than-anticipated 1% comparable retail sales decline, signaling early stabilization. Meanwhile, Reckitt Benckiser announced a major divestment, selling the majority of its Essential Home unit for up to $4.8 billion, and Bridgepoint reported lower H1 profit despite an 11% rise in management fee income.

Analysis

Divergent corporate performance defined UK market activity, with significant single-stock movements driven by regulatory and operational updates. GSK (LON:GSK) experienced a material setback, with its shares falling over 6% after a U.S. FDA advisory panel voted against the benefit-risk profile of its cancer treatment, Blenrep. This non-binding recommendation introduces considerable uncertainty for the drug's approval, expected by July 23. In contrast, luxury brand Burberry (LON:BRBY) showed signs of resilience, with a comparable retail sales decline of only 1%, outperforming analyst expectations of a 3% fall and signaling early stabilization. However, reported revenue was down 6% to £433 million, impacted by a 4% currency headwind. Elsewhere, Reckitt Benckiser (LON:RKT) announced a significant strategic divestiture, agreeing to sell the majority of its Essential Home business to Advent International in a deal valued up to $4.8 billion, while retaining a 30% stake. Meanwhile, Bridgepoint Group (LON:BPTB) reported a decline in first-half profit before tax to £60.6 million from £99.9 million, despite an 11% like-for-like increase in management fee income, indicating potential pressure on profitability outside of core fees.

Key Decisions for Investors

• Investors in GSK should brace for continued volatility and headline risk leading up to the FDA's final decision on Blenrep by July 23, as the negative advisory panel vote significantly clouds the drug's prospects.
• Burberry's better-than-expected sales performance suggests its turnaround may be gaining traction, presenting a potential opportunity, though investors must monitor the ongoing impact of adverse currency movements on reported earnings.
• The divestiture by Reckitt Benckiser is a significant restructuring that will unlock capital and streamline its portfolio; shareholders should evaluate management's future capital allocation strategy and the growth profile of the remaining business.
• For Bridgepoint, the divergence between rising management fees and falling overall profit requires closer scrutiny of the firm's other income streams and cost structure to assess the quality of its earnings.